Refine
Year of publication
Has Fulltext
- yes (1237)
Is part of the Bibliography
- no (1237)
Keywords
- Heavy Ion Experiments (20)
- BESIII (16)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- e +-e − Experiments (11)
- LHC (9)
- Branching fraction (8)
- Heavy-ion collision (6)
- Quarkonium (6)
- Hadronic decays (5)
- Particle and Resonance Production (5)
- ALICE experiment (4)
- Branching fractions (4)
- Charm physics (4)
- Collective Flow (4)
- Electroweak interaction (4)
- Exotics (4)
- Jets (4)
- Lepton colliders (4)
- QCD (4)
- Quark-Gluon Plasma (4)
- Spectroscopy (4)
- ALICE (3)
- Charm Physics (3)
- Charmed mesons (3)
- Experimental nuclear physics (3)
- Experimental particle physics (3)
- Heavy Ions (3)
- Initial state radiation (3)
- Jets and Jet Substructure (3)
- Particle and resonance production (3)
- e+-e− Experiments (3)
- pp collisions (3)
- Beauty production (2)
- Bhabha (2)
- Charmonium (2)
- Cross section (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Früherkennung (2)
- Hadronic cross section (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Leptonic, semileptonic & radiative decays (2)
- Mammakarzinom (2)
- Muon anomaly (2)
- Nachsorge (2)
- Particle Correlations and Fluctuations (2)
- Particle correlations and fluctuations (2)
- Particle decays (2)
- Pb–Pb collisions (2)
- Pion form factor (2)
- Richtlinie (2)
- Single electrons (2)
- Superficial vein thrombosis (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- 900 GeV (1)
- ALICE detector (1)
- Absolute branching fraction (1)
- Alcohol consumption (1)
- Angular distribution (1)
- Annihilation (1)
- Anti-nuclei (1)
- BESIII detector (1)
- Benign disorder (1)
- Blood pressure (1)
- Boosted Jets (1)
- Born cross section measurement (1)
- CP violation (1)
- CTLA-4 (1)
- Cancer (1)
- Cardiovascular biology (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charmonium (-like) (1)
- Clinical Trials and Observations (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Covariance matrix (1)
- Cross section measurements (1)
- D meson (1)
- D0 and D+ mesons (1)
- Dalitz decay (1)
- Dark photon (1)
- Dark sector (1)
- Decision making (1)
- Depression (1)
- Diagnostic markers (1)
- D⁰ meson (1)
- Effectivity (1)
- Electromagnetic amplitude (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Elliptic flow (1)
- Emotions (1)
- FOS: Physical sciences (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Fondaparinux (1)
- Form factors (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadrons (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Hyperons (1)
- Immunology (1)
- Inclusive branching fraction (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- K0S (1)
- Langerhans cell histiocytosis (1)
- Lemperle (1)
- Low-molecular-weight heparin (1)
- Lymphoid Neoplasia (1)
- Malignancy (1)
- Material budget (1)
- Mental health and psychiatry (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Neutrinos (1)
- Nuclear modification factor (1)
- Observational (1)
- Observational studies (1)
- Oncology (1)
- PD-1 (1)
- PYTHIA (1)
- Particle phenomena (1)
- Pb–Pb (1)
- Phase (1)
- Planning target volume (1)
- Polarization (1)
- Production Cross Section (1)
- Prognostic markers (1)
- Properties of Hadrons (1)
- Proton (1)
- Proton–proton (1)
- Quantum chromodynamics (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- R value (1)
- Radiation induced diarrhoea (1)
- Radiotherapy (1)
- Rapidity Range (1)
- Rare decays (1)
- Rare disease (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Risk assessment (1)
- SUV (1)
- Selenium administration in gynecologic radiation oncology (1)
- Semi-leptonic decays (1)
- Single muons (1)
- Strong amplitude (1)
- Systematic Uncertainty (1)
- TR (1)
- Techniques Electromagnetic calorimeters (1)
- Testosterone (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Treatment (1)
- Trigger (1)
- Triple quarkonia (1)
- Vector Boson Production (1)
- Venous thrombosis (1)
- W-exchange (1)
- Xenon-based gas mixture (1)
- Y (4260) (1)
- Y states (1)
- advanced melanoma (1)
- anti-angiogenic therapy (1)
- antibodies (1)
- antihelix shaping (1)
- b-cell lymphomas (1)
- bendamustine (1)
- branching fractions (1)
- center-of-mass energy (1)
- charmed baryon (1)
- charmonium-like states (1)
- chemotherapy regimen (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- complete response (1)
- dE/dx (1)
- decay (1)
- decays (1)
- detector (1)
- dimuon (1)
- diphoton (1)
- discontinuation (1)
- disease progression (1)
- dynamic 18F-FDG PET/CT (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− annihilation (1)
- electron-positron collision (1)
- experimental results (1)
- fondaparinux (1)
- glioblastoma (1)
- hadron spectroscopy (1)
- hadronic events (1)
- heavy ion experiments (1)
- helicity amplitude analysis (1)
- hematopoietic stem cell transplantation (1)
- immune checkpoint blockade (1)
- inclusive J/ψ decays (1)
- leukapheresis (1)
- liver metastasis (1)
- low molecular weight heparin (1)
- luminosity (1)
- lymphoma (1)
- macrophage polarization (1)
- miRNAs (1)
- number of J/ψ events (1)
- otoplasty (1)
- pazopanib (1)
- protruding ear (1)
- quark gluon plasma (1)
- rituximab (1)
- second-line immunotherapy (1)
- soft tissue sarcoma (STS) (1)
- spectra (1)
- targeted therapy (1)
- tetraquark (1)
- therapy resistance (1)
- treatment (1)
- treatment resistance (1)
- trigger efficiency (1)
- tumor angiogenesis (1)
- two-tissue compartment model (1)
- uveal melanoma (1)
- venous thrombosis (1)
- ventral otoplasty (1)
- Λ+c baryon (1)
- Λc⁺ (1)
- Σ hyperon (1)
- ψ(3686) (1)
- √sN N = 2.76 TeV (1)
Institute
Using data samples collected with the BESIII detector operating at the BEPCII storage ring at center-of-mass energies from 4.178 to 4.600 GeV, we study the process eþe− → π0Xð3872Þγ and search for Zcð4020Þ0 → Xð3872Þγ. We find no significant signal and set upper limits on σðeþe− → π0Xð3872ÞγÞ · BðXð3872Þ → πþπ−J=ψÞ and σðeþe− → π0Zcð4020Þ0Þ · BðZcð4020Þ0 → Xð3872ÞγÞ · BðXð3872Þ → πþπ−J=ψÞ for each energy point at 90% confidence level, which is of the order of several tenths pb.
We measure the inclusive semielectronic decay branching fraction of the D+s meson. A double-tag technique is applied to e+e− annihilation data collected by the BESIII experiment at the BEPCII collider, operating in the center-of-mass energy range 4.178–4.230 GeV. We select positrons fromD+s→Xe+νe with momenta greater than 200 MeV/c and determine the laboratory momentum spectrum, accounting for the effects of detector efficiency and resolution. The total positron yield and semielectronic branching fraction are determined by extrapolating this spectrum below the momentum cutoff. We measure the D+s semielectronic branching fraction to be(6.30±0.13(stat.)±0.09(syst.)±0.04(ext.))%, showing no evidence for unobserved exclusive semielectronic modes. We combine this result with external data taken from literature to determine the ratio of the D+s and D0 semielectronic widths, Γ(D+s→Xe+νe)Γ(D0→Xe+νe)=0.790±0.016(stat.)±0.011(syst.)±0.016(ext.). Our results are consistent with and more precise than previous measurements.
Objective: Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions.
Methods: Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding.
Results: A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was below the knee in 54.5%, above the knee in 26.7%, above and below the knee in 18.8%. At baseline, 93.6% received pharmacological treatment (65.7% fondaparinux, 23.2% heparins, 4.3% direct oral anticoagulants [DOACs], 14.5% analgesics), 77.0% compression treatment, and 1.9% surgery; 6.4% did not receive any anticoagulation. The primary outcome occurred in 5.8%; 4.7% had recurrent or extended SVT, 1.7% DVT, and 0.8% PE. Clinically relevant non-major bleeding occurred in 1.2% and major bleeding in 0.3%. Complete clinical recovery of SVT was reported in 708 patients (62.4%). Primary outcome adjusted by propensity score and for treatment duration was lower with fondaparinux compared with low molecular weight heparin (4.4% vs. 9.6%; hazard ratio [HR] 0.51; 95% confidence interval [CI] 0.3 - 0.9; p = .017). On multivariable analysis, associated factors for primary outcome included another SVT prior to the present SVT event (HR 2.3), age per year (HR 0.97), duration of drug treatment per week (HR 0.92), and thrombus length (HR 1.03).
Conclusion: At three month follow up, patients with isolated SVT are at risk of thromboembolic complications (mainly recurrent or extended SVT), despite anticoagulation. In this real life study, about one third had received either heparins, oral anticoagulants, or no anticoagulation.
Introduction: For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radiotherapy, is the mainstay of treatment and the only potentially curative modality. Since surgery is often complicated by large tumour size and extensive tumour vasculature, preoperative treatment strategies with the aim of devitalising the tumour are being explored. One option is treatment with antiangiogenic drugs. The multikinase inhibitor pazopanib, which possesses pronounced antiangiogenic effects, has shown activity in metastatic and unresectable STS, but has so far not been tested in the preoperative setting.
Methods and analysis: This open-label, multicentre phase II window-of-opportunity trial assesses pazopanib as preoperative treatment of resectable STS. Participants receive a 21-day course of pazopanib 800 mg daily during wait time for surgery. Major eligibility criteria are resectable, high-risk adult STS of any location, or metachronous solitary STS metastasis for which resection is planned, and adequate organ function and performance status. The trial uses an exact single-stage design. The primary end point is metabolic response rate (MRR), that is, the proportion of patients with >50% reduction of the mean standardised uptake value (SUVmean) in post-treatment compared to pre-treatment fluorodeoxyglucose positron emission tomography CT. The MRR below which the treatment is considered ineffective is 0.2. The MRR above which the treatment warrants further exploration is 0.4. With a type I error of 5% and a power of 80%, the sample size is 35 evaluable patients, with 12 or more responders as threshold. Main secondary end points are histopathological and MRI response, resectability, toxicity, recurrence-free and overall survival. In a translational substudy, endothelial progenitor cells and vascular epithelial growth factor receptor are analysed as potential prognostic and predictive markers.
Ethics and dissemination: Approval by the ethics committee II, University of Heidelberg, Germany (2012-019F-MA), German Federal Institute for Drugs and Medical Devices (61-3910-4038155) and German Federal Institute for Radiation Protection (Z5-22463/2-2012-007).
Trial registration number: NCT01543802, EudraCT: 2011-003745-18; Pre-results.
The outcome of high-risk soft tissue sarcoma (STS) is poor with radical surgery being the only potentially curative modality. Pazopanib is a multikinase inhibitor approved for the treatment of metastatic STS. Herein, in terms of the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS) trial, we evaluate the potential role of kinetic analysis of fludeoxyglucose F-18 (18F-FDG) data derived from the application of dynamic positron emission tomography/computed tomography (PET/CT) in response assessment to pazopanib of STS patients scheduled for surgical resection. Sixteen STS patients treated with pazopanib as neoadjuvant therapy before surgery were enrolled in the analysis. All patients underwent dynamic PET/CT prior to and after pazopanib treatment. Data analysis consisted of visual (qualitative) analysis of the PET/CT scans, semi-quantitative evaluation based on standardized uptake value (SUV) calculations, and quantitative analysis of the dynamic 18F-FDG PET data, based on two-tissue compartment modeling. Resection specimens were histopathologically assessed and the percentage of regression grade was recorded in 14/16 patients. Time to tumor relapse/progression was also calculated. In the follow-up, 12/16 patients (75%) were alive without relapse, while four patients (25%) relapsed, among them one patient died. Median histopathological regression was 20% (mean 26%, range 5–70%). The studied population was dichotomized using a histopathological regression grade of 20% as cut-off. Based on this threshold, 10/14 patients (71%) showed partial remission (PR), while stable disease (SD) was seen in the rest 4 evaluable patients (29%). Semi-quantitative evaluation showed no statistically significant change in the widely used PET parameters, SUVaverage and SUVmax. On the other hand, 18F-FDG kinetic analysis revealed a significant decrease in the perfusion-related parameter K1, which reflects the carrier-mediated transport of 18F-FDG from plasma to tumor. This decrease can be considered as a marker in response to pazopanib in STS and could be due to the anti-angiogenic effect of the therapeutic agent.
Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice
(2022)
Highlights
• In acute isolated SVT, the prevalence of cancer is almost 7 %.
• Cancer increases the SVT-associated VTE risk at 3 and 12 months.
• Cancer patients with isolated SVT may benefit from prolonged anticoagulation.
Abstract
Background: Despite significant progress in the understanding of paraneoplastic deep vein thrombosis (DVT) and pulmonary embolism (PE), little is known about the outcomes of cancer-associated superficial vein thrombosis (SVT) in daily practice.
Methods: INSIGHTS-SVT was a prospective observational study on patients with acute isolated SVT. Primary outcome measure was symptomatic venous thromboembolism (VTE), a composite of DVT, PE, and SVT extension/recurrence, at 3 months. Clinically relevant bleeding was also assessed.
Results: Of 1151 patients included, 6.7 % either had active cancer at baseline or were diagnosed with cancer during 12 months of follow-up. At 3 months, symptomatic VTE had occurred in 13.0 % and 5.4 % of cancer and non-cancer patients, respectively (HR 2.6, 95 % CI 1.3–5.0). Regarding secondary outcomes, cancer patients had increased risks of DVT and PE (HR 3.9, 95 % CI 1.3–11.8) and hospitalization due to VTE (HR 11.0, 95 % CI 2.5–49.0). The rate of clinically relevant bleeding was numerically higher in the cancer cohort (3.9 % vs 1.3 %, HR 3.1, 95 % CI 0.9–10.7). At 12 months, the primary composite outcome had occurred in 15.6 % and 11.9 % of cancer and non-cancer patients, respectively (HR 1.9, 95 % CI 1.0–3.5). After adjusting for additional risk factors, including age, history of DVT/PE and cardiovascular risk factors/diseases, the association of cancer with the primary outcome remained statistically significant.
Conclusion: Cancer patients with isolated SVT are at significant risk of symptomatic VTE. While most events occur within 3 months, the VTE risk remains elevated up to one year of follow-up.
ClinicalTrials.gov identifier: NCT02699151.
This paper reports on Monte Carlo simulation results for future measurements of the moduli of time-like proton electromagnetic form factors, |GE | and |GM|, using the ¯pp → μ+μ− reaction at PANDA (FAIR). The electromagnetic form factors are fundamental quantities parameterizing the electric and magnetic structure of hadrons. This work estimates the statistical and total accuracy with which the form factors can be measured at PANDA, using an analysis of simulated data within the PandaRoot software framework. The most crucial background channel is ¯pp → π+π−,due to the very similar behavior of muons and pions in the detector. The suppression factors are evaluated for this and all other relevant background channels at different values of antiproton beam momentum. The signal/background separation is based on a multivariate analysis, using the Boosted Decision Trees method. An expected background subtraction is included in this study, based on realistic angular distribuations of the background contribution. Systematic uncertainties are considered and the relative total uncertainties of the form factor measurements are presented.
Using a data sample of e+e− collision data corresponding to an integrated luminosity of 2.93 fb−1 collected with the BESIII detector at a center-of-mass energy of s=3.773GeV, we search for the singly Cabibbo-suppressed decays D0→π0π0π0, π0π0η, π0ηη and ηηη using the double tag method. The absolute branching fractions are measured to be B(D0→π0π0π0)=(2.0±0.4±0.3)×10−4, B(D0→π0π0η)=(3.8±1.1±0.7)×10−4 and B(D0→π0ηη)=(7.3±1.6±1.5)×10−4 with the statistical significances of 4.8σ, 3.8σ and 5.5σ, respectively, where the first uncertainties are statistical and the second ones systematic. No significant signal of D0→ηηη is found, and the upper limit on its decay branching fraction is set to be B(D0→ηηη)<1.3×10−4 at the 90% confidence level.
The Born cross sections and effective form factors for process 𝑒+𝑒−→Ξ−¯Ξ+ are measured at eight center-of-mass energies between 2.644 and 3.080 GeV, using a total integrated luminosity of 363.9 pb−1 𝑒+𝑒− collision data collected with the BESIII detector at BEPCII. After performing a fit to the Born cross section of 𝑒+𝑒−→Ξ−¯Ξ+, no significant threshold effect is observed.
The electromagnetic process is studied with the initial-state-radiation technique using 7.5 fb−1 of data collected by the BESIII experiment at seven energy points from 3.773 to 4.600 GeV. The Born cross section and the effective form factor of the proton are measured from the production threshold to 3.0 GeV/ using the invariant-mass spectrum. The ratio of electric and magnetic form factors of the proton is determined from the analysis of the proton-helicity angular distribution.
By using 6.32 fb−1 of data collected with the BESIII detector at center-of-mass energies between 4.178 and 4.226 GeV, we perform an amplitude analysis of the decay D+s ! K0S + 0 and determine the relative fractions and phase differences of different intermediate processes, which include K0S (770)+, K0S (1450)+, K (892)0 +, K (892)+ 0, and K (1410)0 +. With the detection efficiency based on the amplitude analysis results, the absolute branching fraction is measured to be B(D+s ! K0S + 0) = (5.43 ± 0.30stat ± 0.15syst) × 10−3.
Relative fractions and phases of the intermediate decays are determined. With the detection efficiency estimated by the results of the amplitude analysis, the branching fraction of Dþ s → K−Kþπþπ0 decay is measured to be ð5.42 0.10stat 0.17systÞ%.
By analyzing the large-angle Bhabha scattering events e+e− → (γ)e+e− and diphoton events e+e− → (γ)γγ for the data sets collected at center-of-mass (c.m.) energies between 2.2324 and 4.5900 GeV (131 energy points in total) with the upgraded Beijing Spectrometer (BESIII) at the Beijing Electron-Positron Collider (BEPCII), the integrated luminosities have been measured at the different c.m. energies, individually. The results are important inputs for the R value and J/ψ resonance parameter measurements.
Based on an e+e− collision data sample corresponding to an integrated luminosity of 2.93 fb−1 collected with the BESIII detector at √s=3.773 GeV, the first amplitude analysis of the singly Cabibbo-suppressed decay D+→K+K0Sπ0 is performed. From the amplitude analysis, the K∗(892)+K0S component is found to be dominant with a fraction of (57.1±2.6±4.2)%, where the first uncertainty is statistical and the second systematic. In combination with the absolute branching fraction B(D+→K+K0Sπ0) measured by BESIII, we obtain B(D+→K∗(892)+K0S)=(8.69±0.40±0.64±0.51)×10−3, where the third uncertainty is due to the branching fraction B(D+→K+K0Sπ0). The precision of this result is significantly improved compared to the previous measurement. This result also differs from most of theoretical predictions by about 4σ, which may help to improve the understanding of the dynamics behind.
Using 448.1 × 106 ψ(3686) decays collected with the BESIII detector at the BEPCII e+e− storage rings, the branching fractions and angular distributions of the decays χcJ → Ξ−Ξ¯¯¯¯+ and Ξ0Ξ¯¯¯¯0 (J = 0, 1, 2) are measured based on a partial-reconstruction technique. The decays χc1 → Ξ0Ξ¯¯¯¯0 and χc2 → Ξ0Ξ¯¯¯¯0 are observed for the first time with statistical significances of 7σ and 15σ, respectively. The results of this analysis are in good agreement with previous measurements and have significantly improved precision.
We report the first measurements of the absolute branching fractions of D0 → K0 Lϕ, D0 → K0Lη, D0 → K0Lω, and D0 → K0Lη0, by analyzing 2.93 fb−1 of eþe− collision data taken at a center-of-mass energy of 3.773 GeV with the BESIII detector. Taking the world averages of the branching fractions of D0 → K0Sϕ, D0 → K0Sη, D0 → K0Sω, and D0 → K0Sη0, the K0S − K0L asymmetries RðD0; XÞ in these decay modes are obtained. The CP asymmetries in these decays are also determined. No significant CP violation is observed
By analyzing an electron-positron collision data sample corresponding to an integrated luminosity of 2.93 fb−1 taken at the center-of-mass energy of 3.773 GeV with the BESIII detector, we obtain for the first time the absolute branching fractions for seven 𝐷0 and 𝐷+ hadronic decay modes and search for the hadronic decay 𝐷0→𝐾0𝑆𝐾0𝑆𝜋0 with much improved sensitivity. The results are ℬ(𝐷0→𝐾0𝑆𝜋0𝜋0𝜋0)=(7.64±0.30±0.29)×10−3, (𝐷0→𝐾−𝜋+𝜋0𝜋0𝜋0)=9.54±0.30±0.31)×10−3, ℬ(𝐷0→𝐾0𝑆𝜋+𝜋−𝜋0𝜋0)=(12.66±0.45±0.43)×10−3, ℬ(𝐷+→𝐾0𝑆𝜋+𝜋0𝜋0)=(29.04±0.62±0.87)×10−3, ℬ(𝐷+→𝐾0𝑆𝜋+𝜋+𝜋−𝜋0)=(15.28±0.57±0.60)×10−3, ℬ(𝐷+→𝐾0𝑆𝜋+𝜋0𝜋0𝜋0)=(5.54±0.44±0.32)×10−3, ℬ(𝐷+→𝐾−𝜋+𝜋+𝜋0𝜋0)=(4.95±0.26±0.19)×10−3, and ℬ(𝐷0→𝐾0𝑆𝐾0𝑆𝜋0)<1.45×10−4 at the 90% confidence level. Here, the first uncertainties are statistical, and the second ones are systematic. The newly studied decays greatly enrich the knowledge of the 𝐷→¯𝐾𝜋𝜋𝜋 and 𝐷→¯𝐾𝜋𝜋𝜋𝜋 hadronic decays and open a bridge to access more two-body hadronic 𝐷 decays containing scalar, vector, axial, and tensor mesons in the charm sector.
Cross sections of the process 𝑒+𝑒−→𝜋0𝜋0𝐽/𝜓 at center-of-mass energies between 3.808 and 4.600 GeV are measured with high precision by using 12.4 fb−1 of data samples collected with the BESIII detector operating at the BEPCII collider facility. A fit to the measured energy-dependent cross sections confirms the existence of the charmoniumlike state 𝑌(4220). The mass and width of the 𝑌(4220) are determined to be (4220.4±2.4±2.3) MeV/𝑐2 and (46.2±4.7±2.1) MeV, respectively, where the first uncertainties are statistical and the second systematic. The mass and width are consistent with those measured in the process 𝑒+𝑒−→𝜋+𝜋−𝐽/𝜓. The neutral charmonium-like state 𝑍𝑐(3900)0 is observed prominently in the 𝜋0𝐽/𝜓 invariant-mass spectrum, and, for the first time, an amplitude analysis is performed to study its properties. The spin-parity of 𝑍𝑐(3900)0 is determined to be 𝐽𝑃=1+, and the pole position is (3893.1±2.2±3.0)−𝑖(22.2±2.6±7.0) MeV/𝑐2, which is consistent with previous studies of electrically charged 𝑍𝑐(3900)±. In addition, cross sections of 𝑒+𝑒− → 𝜋0𝑍𝑐(3900)0 → 𝜋0𝜋0𝐽/𝜓 are extracted, and the corresponding line shape is found to agree with that of the 𝑌(4220).
During the 2016-17 and 2018-19 running periods, the BESIII experiment collected 7.5 fb -1 of e+e− collision data at center-of-mass energies ranging from 4.13 to 4.44 GeV. These data samples are primarily used for the study of excited charmonium and charmoniumlike states. By analyzing the di-muon process e+e− (γISR/FSR)µ -> +µ-, we measure the center-of-mass energies of the data samples with a precision of 0.6 MeV. Through a run-by-run study, we find that the center-of-mass energies were stable throughout most of the data-collection period.
We report a search for a heavier partner of the recently observed Zcs(3985)− state, denoted as Z′−cs, in the process e+e−→K+D∗−sD∗0+c.c., based on e+e− collision data collected at the center-of-mass energies of s√=4.661, 4.682 and 4.699 GeV with the BESIII detector. The Z′−cs is of interest as it is expected to be a candidate for a hidden-charm and open-strange tetraquark. A partial-reconstruction technique is used to isolate K+ recoil-mass spectra, which are probed for a potential contribution from Z′−cs→D∗−sD∗0 (c.c.). We find an excess of Z′−cs→D∗−sD∗0 (c.c.) candidates with a significance of 2.9σ, after considering systematic uncertainties, at a mass of (4123.5±0.7stat.±1.1syst.)MeV/c2. As the data set is limited in size, the upper limits are evaluated at the 90% confidence level on the product of the Born cross section and the branching fraction of Z′−cs→D∗−sD∗0, σBorn⋅B at the three energy points, under different assumptions of the Z′−cs mass from 4.120 to 4.140 MeV and of the width from 10 to 50 MeV. Under various mass and width assumptions, the upper limits of σBorn⋅B are found to lie in the range of 2∼6, 3∼7 and 3∼6 pb at s√=4.661, 4.682 and 4.699 GeV, respectively. The larger data samples that will be collected in the coming years will allow a clearer picture to emerge concerning the existence and nature of the Z′−cs state.